What different versions of obeticholic acid are available?

Obeticholic acid (Obeticholic acid), this innovative drug has multiple versions and brands in the global pharmaceutical market. Its original developer is Intercept Pharmaceuticals, and it is sold globally under brand names such as OCALIVA. However, due to the important role of obeticholic acid in clinical treatment, many pharmaceutical companies have also launched imitations of the drug, including well-known pharmaceutical companies such as ASEAN Pharmaceuticals in Laos, Beacon Pharmaceuticals in Bangladesh, and Mylan in India.

Although the brands and manufacturers of these generic drugs are different, their drug ingredients remain the same as the original drug obeticholic acid. Currently, the common specifications on the market are mainly 5 mg 30 tablets per box and 10 mg 30 tablets per box. These different versions and strengths of obeticholic acid provide patients with more treatment options and possibilities.

Obeticholic acid received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2016. It is mainly used to treat adult patients with primary cholangitis (PBC). Obeticholic acid has become a new treatment option for patients who cannot tolerate or respond poorly to traditional drugs such as ursodeoxycholic acid (UDCA). It effectively improves the symptoms and quality of life of PBC patients by regulating the synthesis and uptake of bile acids.

Although obeticholic acid has not yet been officially approved for marketing in China, with its widespread use and recognition around the world, it is believed that more Chinese patients will be able to benefit from this drug in the future. For patients and doctors concerned about this drug, understanding the different versions and brands of obeticholic acid and their price differences will help make more informed treatment choices.

Overall, as an innovative drug, obeticholic acid’s existence in multiple versions and brands provides patients with more treatment options and opportunities.